Marie-Louise Fjällskog, Chief Medical Officer from Faron Pharmaceuticals join Proactive London to share her experience and work with bexmarilimab.
The firm recently reported more data indicating longer survival rates for late-stage cancer sufferers treated with its new drug bexmarilimab.
Updated results from the ongoing phase I/II MATINS trial showed 70% of patients receiving the drug had survived nine months compared with 26% for those not treated.
The most survival rates among the 110 Phase II patients were seen in cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients.